All posts by: Michael Zand

About Michael Zand

Keithley’s Korner: Big benefits from Stem Cell Therapy – Ruidoso News

Continue reading

2017-03-02 NEWS

Ruidoso News

Keithley’s Korner: Big benefits from Stem Cell Therapy
Ruidoso News
“It obviously wasn’t going to heal itself, so we had Tim come in and consider stem cell therapy,” Dr. Rath said. “It turns out that we were able to help his body heal itself without putting him through painful knee surgery.” Within a day after the

Continue reading

2017-03-02 NEWS

Genetic Engineering & Biotechnology News

Immunotherapy Thwarted by Mutational Load, Copy Loss Combo
Genetic Engineering & Biotechnology News
Immune checkpoint blockade, a therapy intended to boost the T-cell response to cancer, doesn’t always work, for reasons that aren’t always clear. If the reasons were better understood, this form of immunotherapy could become more effective. Ultimately

and more »

Continue reading

2017-03-02 NEWS

Genetic Literacy Project

Stanford Team Develops Targeted STR Sequencing Approach That Harnesses CRISPR-Cas9
GenomeWeb
NEW YORK (GenomeWeb) – Researchers from Stanford University have developed a targeted sequencing approach for microsatellites that makes use of the CRISPR-Cas9 system to selectively fragment DNA. In a study published in Nature Communications …
‘Superbugs’ could be killed with ‘genetic chainsaw’ version of gene editor CRISPRGenetic Literacy Project
Genome editing: Pressing the ‘delete’ button on DNAPhys.Org
Scientists Have Created A Way to “Delete” DNA in Living CellsFuturism

all 7 news articles »

Continue reading

2017-03-02 NEWS

Complete Cpf1-Based CRISPR Genome Editing System Available
Labmate Online
Integrated DNA Technologies (IDT) is the first genomics company to develop and bring to market a complete ribonucleoprotein-based Cpf1 CRISPR system. The Alt-R™ A.s. Cpf1 CRISPR System inherits the optimised, efficient, and cost-effective traits of

Continue reading

2017-03-02 NEWS

WND.com

Gene therapy leaves terminal cancer patients in complete remission
WND.com
(London Telegraph) A groundbreaking gene therapy treatment which boosts a patient’s own immune cells has been shown to clear disease from one third of terminal patients. US pharmaceutical company Kite Pharma released results from the first six months …
A New Cancer Treatment Has Given Terminal Patients a Second Chance at LifeFuturism
Global Personalized Gene Therapy Treatments For Cancer Industry 2016 Market Research & AnalysisMedgadget (blog)

all 13 news articles »

Continue reading

2017-03-02 NEWS

CNBC

Juno Halts Development of CAR T-Cell Cancer Immunotherapy Candidate JCAR015
Genetic Engineering & Biotechnology News
Juno Therapeutics has halted development of JCAR015, its lead chimeric antigen receptor (CAR) T-cell cancer immunotherapy indicated for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL), nearly 4 months after placing a Phase II …
Juno Therapeutics beats earnings expectations, announces it will drop problem cancer drugGeekWire
Juno Therapeutics’ Q4 Financial Results Overshadowed by Pipeline SetbackMadison.com
Juno ends flagship drug trial after deaths and FDA suspensionsPuget Sound Business Journal (Seattle)
KFGO –OncLive
all 30 news articles »